Q3 2021 CryoLife Inc Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the CryoLife Third Quarter 2021 Financial Conference Call. (Operator Instructions)
At this time, it is my pleasure to turn the floor over to your host, Brian Johnston. Sir, the floor is yours.
This is Pat Mackin, CEO of CryoLife. We posted a solid quarter despite the headwinds caused by the Delta variant. Our results for the third quarter were $72.2 million, 5% growth on a pro forma constant currency basis compared to Q3 2019, which were right in the midpoint of our Q3 guidance. Our performance benefited particularly from our new stent and stent grafts product launches and strength in our On-X aortic valve business in the U.S.
More specifically, in the third quarter of 2021 compared to the third quarter of 2019, our stents and stent graft segment grew 22% and On-X grew 10%, each on a pro forma constant currency basis. The On-X product line growth was led by the On-X aortic valve revenue growth in North America, which grew 16%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
